Newly Opened Phase 3 Study for Low Grade Serous Ovarian Cancer

Video Transcription

Video Summary

In today's webinar, Dr. Rachel Grisham and Dr. Susanna Banerjee discussed a newly opened Phase III study for low-grade serous ovarian cancer, focusing on the RAMP 301 trial evaluating the combination of avutumetinib and dafactinib versus standard therapy in patients with recurrent disease. They emphasized the importance of clinical trials and cutting-edge treatments for women with this type of cancer. Dr. Banerjee highlighted the promising results from the RAMP 201 study, showing high response rates and durability of responses. The RAMP 301 trial is now open globally, offering patients the chance to be randomized to the combination or standard treatment options. They also discussed the importance of molecular testing, including MAP kinase alterations, as well as potential future options like CDK4/6 inhibitors. The webinar concluded with a Q&A session discussing trial timelines, eligibility criteria, and the potential application of the combination therapy in high-grade serous ovarian cancer. Overall, the webinar highlighted the exciting advancements in treatment options for patients with low-grade serous ovarian cancer and the hope for improved outcomes in the future.

Keywords

webinar

Dr. Rachel Grisham

Dr. Susanna Banerjee

Phase III study

low-grade serous ovarian cancer

RAMP 301 trial

avutumetinib